CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling

CytomX has confirmed a Q1'26 readout for additional data from its trial of CX-2051 in colorectal cancer. Read why CTMX stock ...
MedPage Today

Bevacizumab Misses Mark in Untreated Metastatic Bladder Cancer

Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed. Median overall survival (OS) was about 14 months ...
Targeted Oncology

Illuminating the Sequence of Third-Line Therapies in Metastatic CRC

The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...
Endocrinology Advisor

Adding Atezolizumab to Standard Therapy Fails to Improve Survival in Recurrent Ovarian Cancer

Atezolizumab plus standard therapy was not associated with improved survival in advanced recurrent ovarian cancer.
MedPage Today

Marginal Benefits in High-Risk Ovarian Cancer With Addition of Bevacizumab to Chemo

High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...
ascopubs.org

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer

Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial The advantage by FOLFOXIRI + bevacizumab is clinically relevant ...
The American Journal of Managed Care

FDA Approves Third Bevacizumab Biosimilar

Alymsys from Amneal Pharmaceuticals and mAbxience is the third biosimilar referencing Avastin approved in the United States and the second of 3 biosimilar approvals Amneal expects in 2022. The FDA has ...